| Name | Title | Contact Details |
|---|
Verisys is the leading provider of the most comprehensive data, coupled with deep healthcare industry experience to screen, monitor, verify and credential the individuals and entities you care about. Keeping bad actors out of the healthcare system makes it safer for everyone. Featuring FACIS, CheckMedic, ProviderCheck, and more.
Founded in 2011, CareSync is the leading provider of software and services for chronic disease management, combining technology with 24/7 nursing services to facilitate care coordination among patients, family and caregivers and all providers. CareSync provides turnkey Chronic Care Management services as well as a software-only option, allowing practices of any size to easily meet the billing requirements for CPT code 99490. Additionally, CareSync`s certified technology makes it simple for providers to meet Meaningful Use 2 for Data Exchange, Messaging and Timely Access. CareSync patients are at the center of their healthcare, with access to health information, actionable goals, and Comprehensive Care Plan tasks. As a result, CareSync`s patients are experiencing more productive medical appointments and better health outcomes.
Kluwer Health International is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Botanical Laboratories is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Ferndale, WA. To find more information about Botanical Laboratories, please visit www.botlab.com
ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.